For the year ending 2025-12-31, CDNA had -$49,294K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenue | 379,805 |
| Cost of revenue-Service | 59,394 |
| Cost of revenue-Product | 20,738 |
| Cost of revenue-Patient And Digital Solutions | 37,007 |
| Personnel cost | 131,276 |
| Professional and legal fees | 41,973 |
| Research materials and clinical trials expense | 10,197 |
| Depreciation and amortization | 12,033 |
| Stock-based compensation expense | 34,864 |
| Litigation settlement expense | -5,710 |
| Transformational initiative costs | 2,824 |
| Other segment items | 54,317 |
| Interest income, net | 9,174 |
| Net (loss) income | -21,354 |
| Stock-based compensation | 34,864 |
| Asset impairments and write-downs | 0 |
| Impairment of intangible asset and associated construction in progress | 2,258 |
| Depreciation and amortization | 15,018 |
| Amortization of right-of-use assets | 5,398 |
| Realized gain on sale of long-term marketable equity securities, net | 0 |
| Loss on disposal of asset | -48 |
| Gain on settlement of obligation and recovery of written-off investment | 0 |
| Revaluation of common stock warrant liability to estimated fair value | 0 |
| Revaluation of contingent consideration to estimated fair value | 703 |
| Amortization of premium and accretion of discount on marketable securities, net | -1,273 |
| Accounts receivable | -22,521 |
| Inventory | 4,959 |
| Prepaid and other assets | 4,413 |
| Accounts payable | 808 |
| Accrued compensation | -845 |
| Accrued and other liabilities | -3,308 |
| Accrued royalties | 0 |
| Operating lease liabilities, net | -5,997 |
| Deferred taxes | -17 |
| Net cash provided by (used in) operating activities | 42,032 |
| Maturities of marketable securities | 154,671 |
| Purchases of marketable securities | 145,925 |
| Purchase of corporate equity securities | 0 |
| Sale of corporate equity securities | 0 |
| Additions of capital expenditures | 5,913 |
| Acquisition of intangible assets | 675 |
| Acquisition of business, net of cash acquired | 0 |
| Net cash provided by (used in) investing activities | 2,158 |
| Payment of contingent consideration | 1,500 |
| Repurchase and retirement of common stock | 87,768 |
| Proceeds from exercise of warrants | 0 |
| Proceeds from exercise of stock options | 5,723 |
| Proceeds from issuance of common stock under employee stock purchase plan | 2,272 |
| Taxes paid related to net share settlement of restricted stock units | 12,121 |
| Net cash used in financing activities | -93,394 |
| Effect of exchange rate changes on cash and cash equivalents | -90 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -49,294 |
| Cash, cash equivalents, and restricted cash at beginning of period | 115,274 |
| Cash, cash equivalents, and restricted cash at end of period | 65,980 |
CareDx, Inc. (CDNA)
CareDx, Inc. (CDNA)